Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin in New-onset Type 1 Diabetes
NCT01559025Phase 3Unknown
- Sponsor
- Federal University of São Paulo
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vildagliptin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Federal University of São Paulo. Primary endpoint: Beta cell function (C-peptide AUC) at 1 year. Status: unknown.
02
Drugs
vildagliptin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01559025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01559025.